Under the Radar Stocks Showing Hidden Gem Momentum

 bullish.beats
 
  bullish.beats
 
Follow  Message
 
 
 
Streaking.Winners tracks stocks achieving consecutive gains, focusing on consistent performers and market momentum to keep investors informed.
 

•  22 Nov 2025
 

•   ALMS  
   
  0.00%
•   AXGN  
   
  0.00%
•   BRKR  
   
  0.00%
•   GLUE  
   
  0.00%
•   NBTX  
   
  0.00%

$BRKR Bruker Corporation has posted five consecutive days of gains, trading around 47.27 with a 7.18B market cap. Its trend is firmly upward, supported by a 20-day moving average at 40.10 and a 50-day at 36.35, while volume remains close to its 2.89M average. The RSI at 77.27 signals an overbought state, but the steady accumulation suggests demand is broadening as industrial-biotech spending improves. Traders should watch for potential cooling periods given the elevated momentum.

$ALMS Alumis Inc. continues to attract fresh interest, pushing higher for seven straight sessions to reach 7.30 with a market cap of 762M. The surge in volume to 2.41M relative to an 819K average highlights new participation. The RSI sits at an extremely hot 87.95, making it one of the most stretched setups in the group. While optimism around its pharmaceutical pipeline appears to be driving the rally, traders need to remain aware of the binary risks that typically define early-stage biotech names.

$TYRA Tyra Biosciences has delivered eleven consecutive up-days and now trades at 21.12 with a 1.13B valuation. The stock is significantly extended above its key moving averages at 15.64, 14.16, and 11.69, and its RSI of 84.63 reinforces that the move may be ahead of itself. Still, the underlying interest in its precision oncology programs is undeniably strong. Sharp reversals are always a risk in biotech, but the current trend remains powerful.

$AXGN Axogen Inc. is also trending firmly higher, reaching 26.87 with a 1.24B market cap after five days of gains. The 20-day moving average at 21.55 and the 200-day at 15.99 continue to slope upward, reflecting improving sentiment around its peripheral nerve repair technologies. With an RSI of 80.67, traders must handle it carefully, but the steady volume near 903K compared to its 829K average hints at consistently rising interest.

$GLUE Monte Rosa Therapeutics has a more balanced technical posture. Trading at 14.21 with a 926M valuation, it sits comfortably above its rising 20-, 50-, and 200-day moving averages at 12.46, 9.38, and 6.33. Recent coverage from Wells Fargo with a maintained Equal-Weight rating and projected upside of more than 38 percent adds a supportive catalyst. Its RSI of 64.92 leaves room for additional upside without entering the overheated territory seen in peers. The only concern is lighter than usual volume, which may signal either calm accumulation or hesitation ahead of the next move.

$TK Teekay Corporation offers a different flavor from the biotech-heavy group. Trading at 10.24 with an 872M market cap, the marine transportation company continues its upward trend following dividend-related activity and improving sector sentiment. Its RSI of 66.81, along with price stability above the 9.38 and 8.88 moving averages, makes it a cleaner technical setup. However shipping remains cyclical, and macro-driven volatility can quickly reshape expectations.

$NBTX Nanobiotix stands out for its extremely low trading volume at just 28K relative to a 98K average, yet it still maintains a firm upward trend around 20.93 with a 1.04B valuation. With an RSI of 51.61, it is one of the few names not overextended. The upcoming appearance at the Jefferies London Healthcare Conference may become a catalyst for re-rating, though clinical-stage volatility should not be underestimated.

The bottom line is that $GLUE appears to offer the most attractive near-term opportunity due to its reasonable RSI, strong uptrend, analyst-supported upside, and lack of extreme price extension. Traders seeking momentum can still find fuel in names like $TYRA, but those setups come with materially higher risk.

View All Headlines